Investors pay higher multiples to purchase into unlisted pharma firms
The valuations of privately held pharma firms have improved in the
1th 6 months of 2015, a expansion which resulted from the continuous
expansion of the pharma index in the BSE in the previous 4 years,
according to the data from Venture Intelligence, a research service
spotlight on private firm monetary, transactions and their valuations.
According to the records, at slightest 3 out of the top 4 contracts
occurred in the division, has concerned revenue multiples at or over 5x,
while the same was only one during the related time previous year.
1th 6 months of 2015, a expansion which resulted from the continuous
expansion of the pharma index in the BSE in the previous 4 years,
according to the data from Venture Intelligence, a research service
spotlight on private firm monetary, transactions and their valuations.
According to the records, at slightest 3 out of the top 4 contracts
occurred in the division, has concerned revenue multiples at or over 5x,
while the same was only one during the related time previous year.
Investors pay higher multiples to purchase into unlisted pharma firms
2:20 PM
|
|
This entry was posted on 2:20 PM
You can follow any responses to this entry through
the RSS 2.0 feed.
You can leave a response,
or trackback from your own site.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment